All In Biotech

Drug Trial Radar · NCT04938830

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab- Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease

Last checked: Nov 20, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,003 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,003

Actual

Start

Nov 30, 2021

Primary completion

Apr 28, 2025

Study completion Aug 1, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, up to 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety and tolerability of clesrovimab compared to palivizumab as assessed by the proportion of participants experiencing adverse events (AEs).

Conditions

  • RSV Infection

Interventions

  • ClesrovimabBiological

    IM injection

  • PalivizumabBiological

    IM injection

  • PlaceboBiological

    IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Solicited Injection-site Adverse Events (AEs) in RSV Season 1Time frame: Up to 5 days after each dose in RSV Season 1 (Up to ~33 days)
  2. Number of Participants With Solicited Daily Body Temperatures With Fever in RSV Season 1Time frame: Up to 5 days after each dose in RSV Season 1 (Up to ~33 days)
  3. Number of Participants With Solicited Systemic AEs in RSV Season 1Time frame: Up to 5 days after each dose in RSV Season 1 (Up to ~33 days)
  4. Number of Participants With Anaphylaxis/Hypersensitivity AEs of Special Interest (AESI) in RSV Season 1Time frame: Up to 42 days in RSV Season 1
  5. Number of Participants With Rash AESI in RSV Season 1Time frame: Up to 42 days in RSV Season 1
  6. Number of Participants With Nonserious AEs in RSV Season 1Time frame: Up to 42 days in RSV Season 1
  7. Number of Participants With Serious AEs (SAEs) Through the Duration of Participation in RSV Season 1Time frame: Up to 365 days in RSV Season 1

Locations

146 sites in 27 countries. Site status is shown where the registry gives one.

  • Miller Children's & Women's Hospital Long Beach ( Site 0001)

    Long Beach, California

  • Children's Hospital of Orange County ( Site 0047)

    Orange, California

  • Children's Hospital Colorado ( Site 0011)

    Aurora, Colorado

  • Children's National Medical Center ( Site 0020)

    Washington D.C., District of Columbia

  • Orlando Health - Arnold Palmer Hospital-Orlando Health-Arnold Palmer Hospital Pulmonary and Sleep M ( Site 0022)

    Orlando, Florida

  • Nemours Children's Health, Lake Nona Medical City ( Site 0032)

    Orlando, Florida

  • University of South Florida-Department of Pediatrics ( Site 0045)

    Tampa, Florida

  • Morehouse School Of Medicine ( Site 0049)

    Atlanta, Georgia

  • Clinical Research Prime ( Site 0046)

    Idaho Falls, Idaho

  • University of Kentucky HealthCare - Turfland ( Site 0044)

    Lexington, Kentucky

  • Our Lady of the Lake Children's Hospital ( Site 0031)

    Baton Rouge, Louisiana

  • Tulane University School of Medicine ( Site 0010)

    New Orleans, Louisiana

  • M Health Fairview University of Minnesota Masonic Children's Hospital, West Bank-Peds Research ( Site 0037)

    Minneapolis, Minnesota

  • Rutgers University-Pediatric Clinical Research Center ( Site 0007)

    New Brunswick, New Jersey

  • NYU Langone Hospital - Long Island-Pediatrics ( Site 0028)

    Mineola, New York

  • University of Rochester Medical Center ( Site 0017)

    Rochester, New York

  • The University of North Carolina at Chapel Hill ( Site 0035)

    Chapel Hill, North Carolina

  • Duke University ( Site 0021)

    Durham, North Carolina

  • Dayton Children's Hospital ( Site 0053)

    Dayton, Ohio

  • Tribe Clinical Research, LLC ( Site 0002)

    Greenville, South Carolina

  • Driscoll Children's Hospital ( Site 0025)

    Corpus Christi, Texas

  • DHR Health Institute for Research and Development ( Site 0029)

    Edinburg, Texas

  • Christus Children's-Clinical Research Center ( Site 0038)

    San Antonio, Texas

  • University Hospital-Pediatrics ( Site 0019)

    San Antonio, Texas

  • Road Runner Research, Ltd ( Site 0052)

    San Antonio, Texas

  • Intermountain - Primary Children's Hospital ( Site 0026)

    Salt Lake City, Utah

  • Multicare Rockwood Main Clinic-Rockwood Pediatrics ( Site 0004)

    Spokane, Washington

  • Providence Sacred Heart Medical Center & Children's Hospital ( Site 0030)

    Spokane, Washington

  • MultiCare Health System-Baker Center ( Site 0036)

    Tacoma, Washington

  • Mater Misericordiae Limited-Neonatalogy ( Site 0102)

    Brisbane, Queensland, Australia

  • Telethon Kids Institute-Vaccine Trials Group ( Site 0101)

    Nedlands, Western Australia, Australia

  • Alberta Children's Hospital-Department of Pediatrics ( Site 0180)

    Calgary, Alberta, Canada

  • Canadian Center for Vaccinology ( Site 0179)

    Halifax, Nova Scotia, Canada

  • CHU Sainte-Justine ( Site 0178)

    Montreal, Quebec, Canada

  • Clínica Alemana de Santiago-Neonatology department ( Site 0207)

    Santiago, Region M. de Santiago, Chile

  • Hospital Roberto del Río-Infectología Pediátrica ( Site 0205)

    Santiago, Region M. de Santiago, Chile

  • Hospital Padre Hurtado-NEONATOLOGY/PEDIATRICS ( Site 0201)

    Santiago, Region M. de Santiago, Chile

  • Fundación Hospitalaria San Vicente de Paúl ( Site 0233)

    Medellín, Antioquia, Colombia

  • Clínica Universitaria Bolivariana ( Site 0227)

    Medellín, Antioquia, Colombia

  • Ciensalud Ips S A S ( Site 0235)

    Barranquilla, Atlántico, Colombia

Showing 40 of 146 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.